Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production

Executive Summary

Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.

You may also be interested in...



ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test

After federal agencies invested almost $500m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. It's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.

Government Investment Pays Off: Cue Health Gets EUA For At-Home OTC COVID-19 Test

After the US government invested almost half a billion dollars to ensure Cue Health could scale up production, the FDA announced the self-administered test will now be available over the counter.

Global Initiative Orders 120 Million Abbott, SD Biosensor COVID-19 Rapid Antigen Tests

Tests will be priced at under $5 each for low- and middle-income countries.

Related Content

Topics

UsernamePublicRestriction

Register

MT142898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel